PMC:7195088 / 32607-32950 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T38","span":{"begin":91,"end":104},"obj":"Body_part"},{"id":"T39","span":{"begin":91,"end":102},"obj":"Body_part"},{"id":"T40","span":{"begin":127,"end":135},"obj":"Body_part"}],"attributes":[{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T169","span":{"begin":190,"end":198},"obj":"Disease"}],"attributes":[{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T183","span":{"begin":91,"end":104},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T184","span":{"begin":205,"end":210},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T440","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T441","span":{"begin":44,"end":55},"obj":"Chemical"},{"id":"T442","span":{"begin":205,"end":210},"obj":"Chemical"},{"id":"T443","span":{"begin":308,"end":314},"obj":"Chemical"}],"attributes":[{"id":"A440","pred":"chebi_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A441","pred":"chebi_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A442","pred":"chebi_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A443","pred":"chebi_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T262","span":{"begin":200,"end":249},"obj":"Sentence"},{"id":"T263","span":{"begin":250,"end":343},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days)."}